A Case of Drug Eruption Suspected to be Caused by SGLT2 Inhibitor Therapy Based on the Clinical Course in a Patient with Type 2 Diabetes

DOI Web Site 1 Citations
  • Kitamoto Yuka
    Department of Diabetology and Endocrinology, Saiseikai Noe Hospital
  • Morita Sei
    Department of Diabetology and Endocrinology, Saiseikai Noe Hospital
  • Santo Tomohiro
    Department of Diabetology and Endocrinology, Saiseikai Noe Hospital
  • Koie Motoya
    Department of Diabetology and Endocrinology, Saiseikai Noe Hospital
  • Ishida Yoshihiro
    Department of Dermatology, Saiseikai Noe Hospital
  • Fukushima Mitsuo
    Division of Clinical Nutrition and Internal Medicine, Faculty of Health and Welfare, Okayama Prefectural University
  • Yasuda Koichiro
    Department of Diabetology and Endocrinology, Saiseikai Noe Hospital

Bibliographic Information

Other Title
  • ルセオグリフロジンによる薬疹が経過より疑われた2型糖尿病の1例
  • 症例報告 ルセオグリフロジンによる薬疹が経過より疑われた2型糖尿病の1例
  • ショウレイ ホウコク ルセオグリフロジン ニ ヨル ヤクシン ガ ケイカ ヨリ ウタガワレタ 2ガタ トウニョウビョウ ノ 1レイ

Search this article

Abstract

We herein report a case of a drug eruption suspected to be caused by SGLT2 inhibitors in a patient with type 2 diabetes. The patient was a 63-year-old woman who had been treated with sitagliptin and glimepiride. Her HbA1c level had been approximately 8 %; therefore, luseogliflozin was added to her regimen. On the eighth day of luseogliflozin treatment, she developed erythema on her neck, which later spread to her limbs and trunk. Neither the cessation of luseogliflozin treatment nor administration of steroids by a local physician improved her symptoms, and she was subsequently admitted to our hospital. A dermatologist suspected that luseogliflozin had caused the drug eruption. Consequently, the patient was treated with intravenous prednisolone at a dose of 40 mg per day, which improved the erythema. She was discharged after the steroid dose was gradually reduced (the oral prednisolone dose was tapered to 10 mg per day). Based on the patient's clinical course and biopsy results, the drug eruption was suspected to have been caused by luseogliflozin. Therefore, it is important to inform patients that they should be examined by a dermatologist as soon as possible if they develop a skin rash after taking SGLT2 inhibitors.

Journal

Citations (1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top